Filing Flows › Precigen (PGEN) › Guidance & outlook

Precigen (PGEN) guidance and outlook

Precigen (PGEN) gave its guidance on Nov 5, 2026: Operating cash flow $11.9M for FY2026. Precigen's 10-Q filed Nov 4, 2026 makes 17 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 5, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 4, 2026

• We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
• We estimate that there are approximately 27,000 adult patients in the United States living with RRP.
• PRGN-2009, an investigational non-replicating adenoviral vector-based immunotherapy, based on our AdenoVerse platform, is designed to activate the immune system to recognize and target human papillomavirus-positive, or HPV+, solid tumors.
• Guided by our bioinformatics analysis and in silico protein engineering, PRGN-2009 encodes for a novel, multi-epitope antigen design to target HPV16 and HPV18 infected cells and potentially differentiates from the competition.
• PRGN-3006 is an investigational autologous CAR-T therapy that utilizes our UltraCAR-T platform to express a CAR to target CD33 (Siglec-3), mbIL15 and a kill switch gene.
• PRGN-3005 is an investigational autologous CAR-T therapy that utilizes our UltraCAR-T platform to simultaneously express a CAR targeting the unshed portion of the Mucin 16 antigen, mbIL15, and kill switch genes.
• Looking ahead, we expect that the majority of our future revenues for the foreseeable future will be derived from sales of Papzimeos as we continue to expand our commercial activities and market presence.
• In 2025, revenues generated by Exemplar became less significant to us, and we expect this significance to greatly diminish into the future.
• We do not anticipate that we will be recognizing material collaboration revenue in the near term, except in cases of future strategic transactions involving our platforms, products and programs.
• As a result, we expect cost of products for Papzimeos in future periods, excluding any significant period costs, to primarily reflect inventory capitalized at full production cost, and therefore to increase (exclusive of period costs) as a percentage of Papzimeos product revenue compared with periods in which pre-launch inventory was sold.
• Additionally, we plan to initiate a clinical trial to evaluate safety and efficacy of zopapogene imadenovec-drba in pediatric RRP patients.
• The prior-year increase in warrant liabilities was mainly driven by a rise in Precigen’s stock price and, to a lesser extent, by an increase in the liability for additional warrants that were expected at that point to be issued as paid-in-kind dividends on the Company’s then outstanding Series A Preferred Stock.

Precigen's latest quarter

Questions

Did Precigen raise or lower its guidance?

Precigen (PGEN) gave its guidance on Nov 5, 2026: Operating cash flow $11.9M for FY2026.

What does Precigen expect?

We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We estimate that there are approximately 27,000 adult patients in the United States living with RRP. PRGN-2009, an investigational non-replicating adenoviral vector-based immunotherapy, based on our AdenoVerse platform, is designed to activate the immune system to recognize and target human papillomavirus-positive, or HPV+, solid tumors.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.